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ABSTRACT Candida auris has emerged as a multidrug-resistant pathogen of great
clinical concern. Approximately 90% of clinical C. auris isolates are resistant to
fluconazole, the most commonly prescribed antifungal agent, and yet it remains
unknown what mechanisms underpin this fluconazole resistance. To identify
novel mechanisms contributing to fluconazole resistance in C. auris, fluconazole-
susceptible C. auris clinical isolate AR0387 was passaged in media supplemented
with fluconazole to generate derivative strains which had acquired increased flu-
conazole resistance in vitro. Comparative analyses of comprehensive sterol profiles,
[3H]fluconazole uptake, sequencing of C. auris genes homologous to genes known
to contribute to fluconazole resistance in other species of Candida, and relative ex-
pression levels of C. auris ERG11, CDR1, and MDR1 were performed. All fluconazole-
evolved derivative strains were found to have acquired mutations in the zinc-cluster
transcription factor-encoding gene TAC1B and to show a corresponding increase in
CDR1 expression relative to the parental clinical isolate, AR0387. Mutations in TAC1B
were also identified in a set of 304 globally distributed C. auris clinical isolates repre-
senting each of the four major clades. Introduction of the most common mutation
found among fluconazole-resistant clinical isolates of C. auris into fluconazole-
susceptible isolate AR0387 was confirmed to increase fluconazole resistance by
8-fold, and the correction of the same mutation in a fluconazole-resistant isolate,
AR0390, decreased fluconazole MIC by 16-fold. Taken together, these data demon-
strate that C. auris can rapidly acquire resistance to fluconazole in vitro and that mu-
tations in TAC1B significantly contribute to clinical fluconazole resistance.
IMPORTANCE Candida auris is an emerging multidrug-resistant pathogen of global
concern, known to be responsible for outbreaks on six continents and to be com-
monly resistant to antifungals. While the vast majority of clinical C. auris isolates are
highly resistant to fluconazole, an essential part of the available antifungal arsenal,
very little is known about the mechanisms contributing to resistance. In this
work, we show that mutations in the transcription factor TAC1B significantly con-
tribute to clinical fluconazole resistance. These studies demonstrated that muta-
tions in TAC1B can arise rapidly in vitro upon exposure to fluconazole and that a
multitude of resistance-associated TAC1B mutations are present among the ma-
jority of fluconazole-resistant C. auris isolates from a global collection and appear
specific to a subset of lineages or clades. Thus, identification of this novel genetic
determinant of resistance significantly adds to the understanding of clinical antifun-
gal resistance in C. auris.
Citation Rybak JM, Muñoz JF, Barker KS, Parker
JE, Esquivel BD, Berkow EL, Lockhart SR, Gade L,
Palmer GE, White TC, Kelly SL, Cuomo CA,
Rogers PD. 2020. Mutations in TAC1B: a novel
genetic determinant of clinical fluconazole
resistance in Candida auris. mBio 11:e00365-20.
https://doi.org/10.1128/mBio.00365-20.
Editor Judith Berman, Tel Aviv University
Copyright © 2020 Rybak et al. This is an open-
access article distributed under the terms of
the Creative Commons Attribution 4.0
International license.
Address correspondence to P. David Rogers,
drogers@uthsc.edu
Received 14 February 2020



















KEYWORDS Candida, triazole, resistance, efflux, CRISPR, WGS, antifungal resistance,
drug efflux
First identified in 2009, Candida auris has rapidly become a health care-associatedand multidrug-resistant pathogen of global concern (1, 2). While originally found to
be the causative pathogen of virtually simultaneous outbreaks of invasive candidiasis in
Asia, South Africa, and South America, C. auris has now been identified in more than 30
countries across 6 continents, including more than 900 confirmed clinical cases of C.
auris infections in the United States (3). Further contributing to the clinical significance
of this organism are its proclivity to colonize both environmental surfaces and patients,
challenges associated with reliable identification in the clinical microbiology laboratory,
and the markedly decreased susceptibility to currently available antifungal agents
found in a large proportion of C. auris clinical isolates (4, 5). While epidemiological data
and clinical experience pertaining to the treatment of infections caused by C. auris are
currently inadequate to support the establishment of epidemiological cutoff values and
true clinical breakpoints, the Centers for Disease Control and Prevention (CDC) has
proposed tentative breakpoints to help guide clinicians on the basis of available
susceptibility data for C. auris clinical isolates. Applying these tentative breakpoints,
approximately 3% of C. auris clinical isolates are resistant to echinocandins, one-third
are resistant to amphotericin B, and 90% are resistant to fluconazole (MIC,32mg/liter;
modal MIC,256mg/liter) (6). Additionally, one-third of clinical isolates show multidrug
resistance, with elevated MIC levels for agents from two or more different classes of
antifungals, and clinical isolates resistant to all available agents have been repeatedly
reported (7, 8).
The extent of fluconazole resistance among C. auris isolates is particularly concern-
ing as this agent remains the most commonly prescribed antifungal, and many of the
outbreaks of C. auris have occurred in resource-limited settings (2, 8–11). While the
pervasiveness of fluconazole resistance among C. auris clinical isolates substantially
limits therapeutic options of C. auris infections, relatively little is known about the
molecular mechanisms underpinning this resistance. One mechanism of fluconazole
resistance repeatedly identified in C. auris is mutation of the gene encoding the
sterol-demethylase enzyme targeted by the triazoles, ERG11. Three such mutations,
encoding the amino acid substitutions VF125AL (commonly referred to as F126L),
Y132F, and K143R, are frequently reported among fluconazole-resistant clinical isolates,
and associations between these mutations and specific genetic clades of C. auris have
been observed (2). Additionally, the mutations encoding the Y132F and K143R substi-
tutions correspond to mutations known to contribute to triazole resistance in other
species of Candida such as Candida albicans (12). While the direct impact of these ERG11
mutations has not been delineated in C. auris, heterologous expression of C. auris
ERG11 alleles carrying mutations encoding either the Y132F or K143R amino acid
substitution on a low-copy-number episomal plasmid was observed to decrease flu-
conazole susceptibility in a haploid strain of Saccharomyces cerevisiae (13). However,
clinical isolates harboring the same ERG11 mutations and exhibiting a fluconazole MIC
as low as 1 mg/liter have been described previously, as have fluconazole-resistant
isolates of C. auris with no mutation in ERG11, suggesting the presence of yet-to-be-
identified mechanisms of fluconazole resistance (8, 14).
In addition to mutations in ERG11, increased expression of efflux pump-encoding
genes is a common contributor to clinical triazole resistance among multiple species of
Candida (15). Most notable of these is C. glabrata, in which nearly all of the clinical
triazole resistance is attributable to overexpression of the ATP-binding cassette (ABC)-
type efflux pump-encoding genes C. glabrata CDR1 (CgCDR1), CgPDH1, and CgSNQ2
(16). The C. auris genome has recently been revealed to include a substantial number
of efflux pump-encoding genes of both the ABC and major facilitator superfamily (MFS)
classes, and triazole-resistant isolates of C. auris have been observed to exhibit efflux
pump activity greatly exceeding (up to 14-fold higher) that of C. glabrata (17–19).
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Furthermore, the increased expression of the C. auris ABC-type efflux pump-encoding
gene CDR1 has previously been shown to substantially contribute to clinical triazole
resistance (20, 21). At present, however, the genetic determinants underpinning the
increased expression of efflux pump-encoding genes in C. auris remain unidentified.
In this work, we took an unbiased approach utilizing in vitro evolution to create a
collection of isogenic C. auris strains with increased fluconazole resistance, exhibiting
an 8-to-64-fold increase in fluconazole MIC. Characterization of these strains and
analysis of whole-genome sequencing data for over 300 globally distributed C. auris
isolates implicated TAC1B (B9J08_004820), a close homolog of the well-characterized C.
albicans transcriptional regulator CaTAC1, as a novel genetic determinant of clinical
fluconazole resistance. Having identified TAC1B mutations to be present among a large
proportion of fluconazole-resistant clinical isolates, we utilized a Cas9-mediated trans-
formation system both to introduce the most common TAC1B mutation identified
among resistant clinical isolates (encoding A640V) into the fluconazole-susceptible
AR0387 and to correct the A640V-encoding mutation in the previously characterized
and highly fluconazole-resistant AR0390 clinical isolate to the wild-type (WT) sequence.
In both cases, the presence of this prevalent TAC1B mutation was found to be
associated with significant increase in fluconazole MIC, demonstrating that mutations
in TAC1B represent prevalent and significant genetic determinants of fluconazole
resistance among clinical C. auris isolates.
RESULTS
Candida auris rapidly acquires increased fluconazole resistance in vitro. In an
effort to identify novel mechanisms of fluconazole resistance in this emerging
multidrug-resistant pathogen, a collection of isogenic strains with increased flucona-
zole resistance was created via in vitro evolution utilizing the previously described
fluconazole-susceptible C. auris clinical isolate AR0387 (also known as B8441) (Fig. 1).
Briefly, the parental AR0387 was grown in liquid cultures of yeast extract-peptone-
dextrose (YPD) media supplemented with either 8 or 32 mg/liter of fluconazole for 48 h.
Each liquid culture was then plated on the standard antifungal susceptibility testing
FIG 1 Schematic of C. auris fluconazole in vitro evolution experiments. To obtain fluconazole-evolved C. auris strains,
AR0387 was cultured in YPD supplemented with 8 or 32 mg/liter of fluconazole. Cultures were plated on RPMI media
containing the same concentration of fluconazole, and individual colonies were picked for further characterization.
Fluconazole-evolved strains FLU-A and FLU-C were subsequently further passaged in YPD supplemented with 64 and
256 mg/liter of fluconazole, respectively. Cultures were then again plated on RPMI media containing the same concen-
tration of fluconazole, and individual colonies were picked for further characterization.
Candida auris TAC1B Contributes to Triazole Resistance ®













medium, RPMI 1640, supplemented with the same concentration of fluconazole for an
additional 48 h to identify individual colonies exhibiting increased fluconazole resis-
tance. Two individual colonies were randomly selected for characterization from the
plate supplemented with 8 mg/liter of fluconazole (yielding strains FLU-A and FLU-B),
and a single colony was randomly selected from the plate supplemented with 32 mg/
liter of fluconazole (yielding strain FLU-C). Two strains (including one strain each from
the initial passages), FLU-A and FLU-C, were subsequently subjected to a second
passage in 64 and 256 mg/liter of fluconazole supplemented media, respectively,
yielding strains FLU-A2 and FLU-C2.
Fluconazole MICs were then determined for the parental AR0387 and each of the
five fluconazole-evolved strains by broth microdilution in accordance with Clinical and
Laboratory Standards Institute methodology with minor modifications as previously
described (20). AR0387 exhibited a fluconazole MIC of 1 mg/liter, while the five
fluconazole-evolved strains were found to have MICs ranging from 8 to 64 mg/liter
(Fig. 2). Each of the second-generation evolved strains, FLU-A2 and FLU-C2, exhibited
a further 2-to-4-fold increase in fluconazole MIC relative to the corresponding first-
generation strains. Fluconazole MICs for all fluconazole-evolved strains were observed
to be stable following storage at –80°C and multiple passages on fluconazole-free
media.
Fluconazole-evolved strains exhibit alterations in membrane sterols without
accompanying mutations in ERG11 or ERG3. As fluconazole-resistant C. auris clinical
isolates are very often found to possess mutations in ERG11, sequencing of the ERG11
allele for each of the fluconazole-evolved strains was performed. Surprisingly, all
evolved strains were found to have wild-type ERG11 sequences matching that of the
parental AR0387. To assay for other changes to the ergosterol biosynthesis pathway
which may have been contributing to fluconazole resistance, each of the fluconazole-
evolved strains and the parental AR0387 were subsequently subjected to comprehen-
sive sterol profiling. Briefly, each strain was grown to the exponential-growth phase in
RPMI liquid media with or without 16 mg/liter of fluconazole (a concentration approx-
imating the average serum concentration achieved in patients being treated for
candidemia) (22, 23).
Following growth in RPMI media without fluconazole, all of the fluconazole-evolved
strains and the parental AR0387 were observed to have largely similar sterol profiles
(Fig. 3). In all samples, ergosterol comprised more than 75% of total cellular sterols, with
ergosta-5,7,22,24(28)-tetraenol and zymosterol observed to be the next most abundant
sterols. AR0387 and four of the fluconazole-evolved strains (FLU-A, FLU-B, FLU-C, and
FLU-A2) were also observed to have a small amount (2% to 4%) of lanosterol present,
whereas this sterol was absent in the FLU-C2 strain.
Following growth in RPMI media supplemented with fluconazole, the sterol profiles
of each of the fluconazole-evolved strains were dramatically different from that of
FIG 2 Elevated fluconazole MIC observed among C. auris fluconazole-evolved strains. Percent growth of
AR0387 and fluconazole-evolved strains with escalating concentrations of fluconazole was measured at
24 h. Percent growth was determined relative to respective untreated controls as assessed by absorbance
at OD600. Growth inhibition of 50% relative to untreated control is shown as a dotted horizontal line. The
fluconazole MIC for each isolate or strain is shown at the right. Error bars for each data point represent
the standard deviations of results from three independent measurements of technical replicates.
Rybak et al. ®













AR0387 (Fig. 4). While ergosterol was still the predominant sterol among all five
fluconazole-evolved strains, lanosterol (46.0%  7.4%) and 14-methyl-fecosterol (21.3% 
4.8%) were observed to be the two most prevalent sterols in AR0387. In Candida
albicans, 14-methyl-fecosterol is a known substrate of the sterol-desaturase enzyme
encoded by CaERG3, which catalyzes the conversion of 14-methyl-fecosterol to the
toxic sterol associated with the antifungal activity of the triazoles, 14-methyl-ergosta-
8,24(28)-dienol-3,6-diol (Fig. 5). Additionally, 14-methyl-ergosta-8,24(28)-dienol-3,6-diol
comprised 3.8% 1.9% all sterols present in AR0387, while this sterol was absent in the
sterol profiles of all fluconazole-evolved strains. As mutations in the sterol-desaturase-
encoding gene ERG3 have been observed to contribute to fluconazole resistance in
other species of Candida and notable differences in the amounts of cellular 14-methyl-
fecosterol and 14-methyl-ergosta-8,24(28)-dienol-3,6-diol were observed between
AR0387 and the fluconazole-evolved strains, sequencing of the C. auris gene
(B9J08_003737) with the highest degree of homology to C. albicans CaERG3 was
performed. However, no mutation in C. auris ERG3 was observed in any of the
fluconazole-evolved strains.
Fluconazole-evolved strains exhibit significantly reduced fluconazole uptake.
As triazoles (including fluconazole) have previously been shown to enter the cells of C.
albicans via facilitated diffusion, deficient drug importation was next examined as a
potential mechanism contributing to the increased fluconazole resistance among the
fluconazole-evolved strains (24). As previously described, the accumulation of [3H]flu-
conazole was assessed for AR0387 and each fluconazole-evolved strain, as well as for a
previously characterized strain of AR0387 where the CDR1 gene had been deleted
(AR0387_Δcdr1), following 2 h glucose starvation in YNB media without carbon source
supplementation (20). [3H]fluconazole accumulation was observed to be reduced by
FIG 3 Sterol profiles of C. auris fluconazole-evolved strains grown in RPMI media are similar to those of the parental
AR0387. The major constituent sterols for AR0387 and fluconazole-evolved strains at the exponential-growth phase
in RPMI media are shown as a proportion of total cellular sterols. Error bars for each data point represent the
standard deviations of results from three independent measurements of technical replicates.
FIG 4 Sterol profiles of C. auris fluconazole-evolved strains grown in RPMI media supplemented with fluconazole
reveal a lack of 14-methyl-ergosta-8,24(28)-dienol-3,6-diol. The major constituent sterols for AR0387 and
fluconazole-evolved strains at the exponential-growth phase in RPMI media are shown as a proportion of total
cellular sterols. Error bars for each data point represent the standard deviations of results from three independent
measurements of technical replicates.
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approximately 50% in four of the fluconazole-evolved strains (FLU-A, FLU-B, FLU-C, and
FLU-A2) relative to than that observed in AR0387, while accumulation in FLU-C2 did not
significantly differ from that in AR0387 (5,438 versus 6,560 cpm, respectively;
P 0.2842) (Fig. 6a). Importantly, there was no difference in [3H]fluconazole accumu-
lation between AR0387 and AR0387_Δcdr1 (6,560 and 6,813 cpm, respectively;
P 0.9976) (Fig. 6b), confirming that the conditions used in this study for glucose
starvation were adequate to remove the activity of this known C. auris resistance
effector.
Mutations in TAC1B are associated with significantly increased expression of
CDR1. Gain-of-function (GOF) mutations in zinc-cluster transcription factor genes, such
as C. albicans genes CaUPC2, CaMRR1, and CaTAC1, represent a well-characterized
mechanism of fluconazole resistance among other species of Candida (15). To deter-
mine if similar mutations might have been contributing to the fluconazole resistance
among the fluconazole-evolved strains in these studies, the C. auris genes with the
highest degree of homology to C. albicans transcriptional regulatory genes CaUPC2,
CaMRR1, and CaTAC1, here named UPC2 (B9J08_000270), MRR1 (B9J08_004061), TAC1A
(B9J08_004819), and TAC1B (B9J08_004820), were identified by BLAST and gene or-
thology analysis and sequencing was performed. As two C. auris genes possessing very
high degrees of homology with CaTAC1 were identified (TAC1A and TAC1B share 25.6%
predicted peptide sequence identity with each other and share 30.6 and 26.9% identity
with CaTAC1, respectively), both were included in this study. While no mutations were
identified in TAC1A or MRR1, all five fluconazole-evolved strains were found to have
mutations encoding amino acid substitutions in TAC1B (Table 1). Both the FLU-A strain
and the corresponding second-generation derivative FLU-A2 were found to harbor a
mutation encoding the amino acid substitution R495G, while the FLU-B, FLU-C, and
FLU-C2 strains were found to possess a mutation encoding the amino acid substitution
F214S. Neither of these mutations corresponds to previously characterized GOF muta-
FIG 5 Predicted C. auris sterol biosynthesis pathway. The major constituent sterols identified in sterol profiles are shown
with corresponding colors.
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tions in CaTAC1 or to orthologous genes from other species of Candida. However, these
mutations are predicted to alter residues near or within the conserved fungal tran-
scription factor middle homology region (MHR) of Tac1Bp, and multiple mutations
encoding amino acid substitutions in the MHR of CaTAC1 have previously been
reported to be associated with fluconazole resistance (25). Additionally, a sole mutation
in UPC2 encoding the amino acid substitution M365I was identified in FLU-C2, and this
mutation similarly alters a residue predicted to reside within the MHR of Upc2p.
In an effort to ascertain if the identified mutations in TAC1B and UPC2 may be
associated with altered expression of potential resistance effectors among the
fluconazole-evolved strains, the relative expression levels of ERG11, CDR1, and MDR1
were evaluated by reverse transcription-quantitative PCR (RT-qPCR). To accomplish this,
AR0387 and each of the fluconazole-evolved strains were grown to the exponential-
growth phase in RPMI media, and RNA was extracted as previously described. The
expression of each gene of interest relative to AR0387 was assessed using the ΔΔCT
(threshold cycle) method and the C. auris ACT1 housekeeping gene (B9J08_000486)
(20). The level of expression of CDR1 was found to be significantly (3-to-5-fold) higher
in all five fluconazole-evolved strains than in AR0387 (P 0.0001 for all evolved strains
compared to AR0387) (Fig. 7). This level of CDR1 expression is similar to that previously
described among extensively fluconazole-resistant C. auris clinical isolates (20). Addi-
tionally, subtle variations in the levels of expression of the ERG11 and MDR1 genes, not
FIG 6 Decreased intracellular accumulation of [3H]fluconazole among fluconazole-evolved strains. [3H]-labeled fluconazole uptake was determined in (a)
fluconazole-evolved strains and (b) a CDR1 deletion strain and was compared to that shown by parental clinical isolate AR0387. FLU, fluconazole. Error bars for
each data point represent standard deviations of results from six independent measurements of technical replicates. Intracellular accumulation of [3H]flucona-
zole was significantly lower in FLU-A, FLU-A2, FLU-B, and FLU-C than in AR0387 (P 0.0021, P 0.0001, P 0.0001, and P 0.0001, respectively), while
accumulation in FLU-C2 did not significantly differ from that seen in AR0387 (P 0.2842) and no difference in accumulation between AR0387 and
AR0387_Δcdr1 was seen (P 0.9976|).
TABLE 1 Sequencing of C. auris MRR1, TAC1A, TAC1B, and UPC2 among fluconazole-
evolved strains
Gene
Clinical isolate or strain
AR0387 FLU-A FLU-A2 FLU-B FLU-C FLU-C2
MRR1 WT WT WT WT WT WT
TAC1A WT WT WT WT WT WT
TAC1B WT R495G R495G F214S F214S F214S
UPC2 WT WT WT WT WT M365I
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exceeding 2.1-fold higher than the levels seen with AR0387, were also observed among
individual fluconazole-evolved strains.
As copy number variations (CNVs) among genes encoding fluconazole resistance
effectors, such as ERG11, have previously been reported among clinical isolates and
laboratory strains of C. auris, qPCR amplifications from genomic DNA were performed
to assay for CNV among the effectors ERG11, CDR1, andMDR1, as well as TAC1B, for each
of the fluconazole-evolved strains. (26, 27). For each gene of interest, three primer sets
spanning the open reading frame were utilized. While no alteration in the copy number
of ERG11, CDR1, or MDR1 was observed, the second-generation fluconazole-evolved
FLU-A2 strain was found to show a 2-fold increase in the copy number of TAC1B, which
was not evident in other evolved strains (see Fig. S1 in the supplemental material).
TAC1B mutations identified during in vitro evolution studies are also present
among fluconazole-resistant C. auris clinical isolates. Interrogation of a data set
consisting of whole-genome sequencing data for 304 globally distributed C. auris
isolates representing each of the four major clades revealed 14 nonsynonymous TAC1B
mutations and one deletion, excluding sites which are fixed in all isolates within a clade
and which are present in both sensitive and resistant isolates (Fig. 8; see also Table S1
in the supplemental material) (27). In total, mutations in TAC1B were identified among
165 (54%) isolates. Additionally, 50% (148) of the isolates in this collection with
available susceptibility data were found to be fluconazole resistant (MIC of 32mg/
liter) and to possess a mutation in TAC1B. Furthermore, the two TAC1B mutations that
arose during in vitro drug selection were found to be present among fluconazole-
resistant clinical C. auris isolates, suggesting a possible role in clinical fluconazole
resistance. R495G was found in a single clade I isolate, and the F214S change was found
FIG 7 Significantly increased relative expression of C. auris CDR1 among fluconazole-evolved strains grown to the exponential-growth phase in RPMI media.
The levels of expression of C. auris ERG11, CDR1, and MDR1 in AR0387 and the fluconazole-evolved strains were determined following culturing to the
exponential-growth phase at 30°C in RPMI media. The expression level for each sample is shown relative to that of the respective gene in AR0387. Arrows
between graphs indicate the lineage of each fluconazole-evolved strain from the parental AR0387. Error bars for each data point represent standard errors of
the means of results from three biological replicates each performed with three technical replicates. The level of expression of C. auris CDR1 among all
fluconazole-evolved strains was observed to be significantly higher (3.3 to 5.4-fold) than that of AR0387 (P 0.0001 for each individual comparison). Differences
in the levels of expression of CDR1 between the sequential evolved strains were not found to be significant (FLU-A versus FLU-A2, P 0.7186; FLU-C versus
FLU-C2, P 0.3855).
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in 2 isolates from clade II and in 1 isolate from clade IV (Fig. 8; see also Table S1).
Notably, a mutation encoding the A640V amino acid substitution was found to be the
most common among clinical isolates, found in 57 clade I isolates from 7 countries and
always present with the ERG11 mutation encoding the K143R amino acid substitution.
Nearly all (98.2%) of the isolates with A640V and K143R mutations displayed high-level
fluconazole resistance (64 mg/liter). Other common TAC1B mutations found included
A657V in 15 clade I isolates and the frameshift mutation F862_N866del in 46 clade IV
isolates. These mutations appeared in isolates with the ERG11 Y132F variant, and these
isolates were found to have markedly high MIC values (Fig. 8), suggesting that these
mutations may provide additive fluconazole resistance effects. Comparison of Tac1B
protein sequences indicated that C. auris A657V corresponds to the CaTac1 GOF
mutation A736V associated with increased triazole resistance in C. albicans. Addition-
ally, we observed three novel TAC1B mutations in clade IV isolates lacking resistance-
associated mutations in ERG11, including K247E (n 5), M653V (n 7), and A651T
(n 16), six resistant isolates from clade I which harbored two TAC1B mutations (A15T
and S195C), and two different mutations affecting the P595 site (P595L in clade I and
P595H in clade IV).
FIG 8 TAC1B point mutations and fluconazole susceptibility in C. auris. (a) Phylogenetic tree of SNPs identified from 304 C. auris whole-genome sequences from
four major clades (I, II, III, and IV). Isolate label backgrounds are color coded for known mutations in ERG11 (B9J08_001448) (Y132F, K143R, F126L). Susceptibility
to fluconazole is depicted as resistant (dark gray) or susceptible (yellow), and the MIC values are indicated as dark-blue boxes. The red dotted line indicates
the tentative fluconazole MIC breakpoint (32 mg/liter). Green circles indicate isolates harboring non-clade-specific nonsynonymous mutations or gain-of-
function mutations in TAC1B (B9J08_004820), with filled circles corresponding to percent alternative allele of 0.8, while open green circles correspond to
percent alternative allele of 0.67 to 0.79. The specific mutation is indicated for each isolate(s). Mutations in bold/dark blue arose in in vitro evolution experiments
or were functionally tested in this study and found to be associated with increased resistance to fluconazole in C. auris. (b) Mutations and locations in TAC1B
protein sequence associated with azole resistance are indicated using triangles. Mutations indicated with bold/dark blue (red triangles) arose in in vitro evolution
experiments or were functionally tested in this study and associated with increased resistance to fluconazole in C. auris. The size of the triangle indicates the
number of isolates from this study harboring the mutation (range, 1 to 57 isolates).
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Mutations in TAC1B contribute to fluconazole resistance. As mutations in TAC1B
were identified in a large proportion of fluconazole-resistant C. auris clinical isolates and
as the mutation encoding the amino acid substitution A640V was found to be the most
prevalent among the members of this large collection of clinical isolates, the direct
impact of this mutation on fluconazole susceptibility was next determined using a
Cas9-mediated transformation system. To accomplish this, the TAC1B allele from the
previously characterized fluconazole-resistant C. auris AR0390 clinical isolate (also
known as B11205, an isolate from clade I), which contains the mutation encoding the
amino acid substitution A640V, was introduced into the fluconazole-susceptible
AR0387 clinical isolate by the use of Cas9 ribonucleoproteins (Cas9-RNP) and the
SAT-FLP system as previously described (20). Two independent positive-testing trans-
formants were obtained, and the fluconazole MICs were determined by broth microdi-
lution. Introduction of the TAC1BA640V allele into the native TAC1B locus was observed
to increase the fluconazole MIC 8-fold relative to the parental AR0387 (Fig. 9). Con-
versely, when the same methods were used to introduce the wild-type TAC1B allele to
isolate AR0390 (which harbors the TAC1Bmutation encoding A640V), a 16-fold decrease
in fluconazole MIC was observed (Fig. 9). The fluconazole MICs did not differ between
independent transformants.
DISCUSSION
C. auris has rapidly become a fungal pathogen of global concern. Among the
characteristics most notably distinguishing this organism from other species of Can-
dida, the prevalence of fluconazole resistance is of clear clinical concern as fluconazole
remains the most commonly prescribed antifungal worldwide. While mutations in the
ERG11 gene are strongly associated with clinical fluconazole resistance in C. auris, the
presence of this mechanism alone poorly explains the entirety of resistance observed
clinically, and the roles of other genetic and molecular mechanisms contributing to
fluconazole resistance in this organism remain largely unknown.
To date, the predominance of knowledge of the molecular mechanisms of flucona-
zole resistance among species of Candida comes from experience studying C. albicans.
In this organism, the most commonly reported mechanisms of fluconazole resistance
include mutations in the gene encoding the target of the triazole antifungals, CaERG11,
and overexpression of either CaERG11 or genes encoding multidrug-efflux pumps such
as CaCDR1, CaCDR2, and CaMDR1 (12, 15, 28). In fact, among a collection of 63
unrelated fluconazole-resistant C. albicans clinical isolates, all were found to exhibit one
of these resistance mechanisms and the vast majority possessed a combination of
mechanisms. Specifically, 87% were found to have missense mutations in CaERG11, 75%
exhibited elevated expression of CaERG11, 77% exhibited elevated expression of
CaCDR1 and CaCDR2, and 21% exhibited elevated expression of CaMDR1 to levels
known to contribute to fluconazole-resistance (12, 28). The increased expression of C.
FIG 9 Fluconazole MIC for TAC1B strains. Percent growth of AR0387 and AR0390 and the corresponding
derivative TAC1B strains with escalating concentrations of fluconazole was measured at 24 h. Percent
growth was determined relative to the corresponding untreated controls as assessed by absorbance at
OD600. Growth inhibition of 50% relative to the untreated control is shown as a dotted horizontal line.
Error bars for each data point represent the standard deviations of results from three independent
measurements of technical replicates.
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albicans fluconazole resistance effectors has been extensively studied and in the
majority of isolates is directly attributable to GOF mutations in zinc-cluster transcription
factor genes such as CaUPC2, CaTAC1, and CaMRR1 (contributing to the increased
expression of CaERG11, both CaCDR1 and CaCDR2, and CaMDR1, respectively) (15,
28–30). Other C. albicansmechanisms of fluconazole resistance, such as loss-of-function
(LOF) mutations in CaERG3, have also been reported but are much less commonly
identified among clinical isolates (31).
In this work, we utilized in vitro evolution to create a collection of isogenic C. auris
strains with elevated fluconazole MICs in an effort to identify novel genetic determi-
nants of fluconazole resistance. Strains with significant (8-fold to 32-fold) increases in
fluconazole MICs were obtained after a total of only 96 h of growth in fluconazole-
supplemented media, and this resistance was observed to be stable after subsequent
culturing on fluconazole-free media. This rapid emergence of increased fluconazole
resistance is particularly concerning, considering that patients being treated for infec-
tions caused by C. auris have acquired antifungal-resistant infections while receiving
therapy and that the fluconazole-resistant strains in these experiments were obtained
after only a single passage in media supplemented with fluconazole at clinically
relevant concentrations (8 to 32 mg/liter) (23). The rapidity of this emergence of
fluconazole resistance may be influenced by the haploid nature of the C. auris genome,
where acquisition of even a recessive mutation may make a larger immediate contri-
bution to resistance than has been found to occur with other diploid species of Candida
such as C. albicans, where a loss-of-heterozygosity event may be required to observe
the maximal impact of a single resistance mutation (32). Furthermore, a notable
proportion of C. auris clinical isolates have been observed to exhibit increased copy
numbers of resistance-associated genes, as was identified in this study with the
increased TAC1B copy numbers seen in the second-generation fluconazole-evolved
FLU-A2 strain (which concomitantly harbored a R495G-encoding mutation in TAC1B)
(27).
Surprisingly, no mutations in C. auris ERG11 were identified among the fluconazole-
evolved strains created in this study, and all five strains were found to harbor one of
two mutations in TAC1B (encoding F214S and R495G), a gene with a high degree of
homology to the well-characterized C. albicans transcriptional regulator gene CaTAC1.
Intriguingly, two of the three first-generation evolved strains, FLU-B and FLU-C, were
found to have acquired the same TAC1Bmutation (F214S) even after selection following
exposure to different concentrations of fluconazole (8 and 32 mg/liter, respectively).
Furthermore, RT-qPCR revealed that each of the five TAC1B mutant strains exhibited
elevated expression of the ABC-type efflux pump-encoding gene CDR1, as has been
observed with clinical C. albicans isolates possessing a GOF mutation in CaTAC1 (29).
Importantly, the degree of CDR1 overexpression observed among fluconazole-evolved
strains was similar to that previously reported among fluconazole-resistant clinical C.
auris isolates (20).
The clinical relevance of mutations in C. auris TAC1B was further corroborated upon
large-scale analysis of whole-genome sequencing data for over 300 C. auris clinical
isolates. Among the members of this global collection, the majority (54%) of the isolates
were found to have mutations in TAC1B, and 90% of all isolates with TAC1B mutations
were resistant to fluconazole. A total of 14 nonsynonymous TAC1B mutations and one
deletion were identified, and this included both of the mutations identified in
fluconazole-evolved strains, as well as a single mutation (encoding A640V) which was
found among 57 clinical isolates of C. auris from clade I. Subsequently, Cas9-RNP-
mediated genetic manipulations demonstrated that the mutation in TAC1B encoding
the A640V amino acid substitution, the most common mutation found among
fluconazole-resistant clinical isolates of C. auris, was sufficient alone to elevate flucona-
zole resistance by 8-fold. Thus, these data definitively demonstrate that mutations in C.
auris TAC1B represent a novel genetic determinant of clinical fluconazole resistance.
Additional characterization of the fluconazole-evolved C. auris strains created in this
study was also performed to identify potential changes in cellular sterol composition
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and fluconazole uptake which might also be associated with increased fluconazole
resistance in C. auris. Previously, analysis of sterol profiles had revealed significant
changes in cellular sterol composition among fluconazole-resistant clinical isolates of
Candida possessing mutations in ergosterol biosynthesis genes. In one example, a
clinical C. albicans isolate with pan-triazole resistance and harboring mutations in both
CaERG11 and CaERG5 was found to produce no detectable ergosterol while instead
accumulating a large amount of ergosta-5,7-dienol (82% of total sterols) (33). More-
subtle sterol profile changes were also reported in a multidrug-resistant clinical isolate
of C. parapsilosis possessing a loss-of-function mutation in CpERG3 (encoding G111R).
This isolate was found to accumulate large amounts of ergosta-7,22-dienol (72% of
total sterols), a substrate of CpERG3 not typically present in such large proportions (22).
Thus, to assay for changes in ergosterol biosynthesis which might be associated
with the fluconazole resistance phenotype, comprehensive sterol profiling of the
fluconazole-evolved C. auris strains was undertaken. Following growth in RPMI media
without fluconazole supplementation, the only notable difference in levels of sterols
among the fluconazole-evolved strains and AR0387 was a lack of detectable lanosterol,
the substrate of ERG11, in the second-generation evolved FLU-C2 strain. It is tempting
to speculate that this lack of lanosterol may be associated with the mutation in UPC2
which is unique to this fluconazole-evolved strain, as GOF mutations in CaUPC2 have
been shown to increase expression of ergosterol biosynthesis genes, including CaERG11
(28). However, further interrogation of the C. auris UPC2 regulon and this potential
resistance-associated mutation is clearly needed to definitively associate this pheno-
type with the observed mutation in C. auris UPC2.
Following growth in RPMI media supplemented with 16 mg/liter (a concentration
representative of the plasma concentration of fluconazole in patients being treated for
candidemia), a stark difference in the sterol profiles of AR0387 and all fluconazole-
evolved strains was observed. Whereas ergosterol remained the principal sterol present
in all fluconazole-evolved strains (comprising more than 50% of sterols), lanosterol
predominated the total cellular sterols in the parental AR0387 isolate (46%). Addition-
ally, 14-methyl-ergosta-8,24(28)-diene-3,6-diol, a sterol proposed to be toxic and im-
portant for the antifungal activity of the triazoles, was uniquely found in AR0387 (4%
of total sterols) in conjunction with a large amount of 14-methyl-fecosterol (21%), the
direct precursor of this speculated toxic sterol (34). However, this change in the sterol
profile of AR0387 under conditions of fluconazole treatment is consistent with previ-
ously reported changes in fungal sterols with suprainhibitory concentrations of flu-
conazole (33, 35). Therefore, these changes in the sterol profile of AR0387 may be
related to the lower fluconazole MIC for this clinical isolate (1 mg/liter) whereas the
maintained ergosterol content observed in fluconazole-evolved strains may be a direct
consequence of the identified mutations in C. auris TAC1B or a result of the decreased
fluconazole sensitivity of these fluconazole-evolved strains. Further investigation of the
TAC1B regulon and the impact of TAC1B mutations on ergosterol biosynthesis and
sterol profiles is required.
While the mechanism of triazole uptake in fungi has remained unknown to date and
decreased drug uptake is not a mechanism which has been demonstrated to contribute
to fluconazole resistance among clinical isolates of Candida, it is has been suggested
that clinical isolates of Candida with reduced fluconazole sensitivity may exhibit altered
fluconazole uptake (24). To interrogate the potential role of altered fluconazole uptake
in the resistance observed among the fluconazole-evolved strains created in this study,
analysis of [3H]fluconazole uptake was performed. Among the fluconazole-evolved
strains, this analysis revealed an intriguing decrease in [3H]fluconazole uptake in 4 of
the 5 strains compared to AR0387. All strains except for FLU-C2 were found to
accumulate approximately 50% less [3H]fluconazole under energy-depleted conditions.
While the reason for the higher degree of [3H]fluconazole uptake in the FLU-C2 strain
remains unknown, again it is tempting to speculate whether the mutation in UPC2
which is unique to this strain may be involved, particularly as it contrasts with the
diminished uptake in the related first-generation evolved FLU-C strain. Further inves-
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tigation of the role of altered fluconazole uptake in resistance among clinical isolates of
C. auris and the impact of mutations in either TAC1B or UPC2 on fluconazole uptake is
clearly merited.
While the findings from the experiments described here are intriguing and of clear
clinical significance, this study also had limitations. The in vitro evolution experiments
described were performed in a single genetic background and using only fluconazole.
Thus, it cannot be determined if different mechanisms of triazole resistance would be
observed if similar studies were conducted with different clinical isolates of C. auris or
different agents of the triazole class of antifungals. Additionally, while similarities
between the fluconazole-evolved strains in this work and clinical isolates of Candida
possessing known GOF mutations in close homologs of TAC1B are apparent, such as the
increased expression of CDR1, further characterization of the C. auris TAC1B regulon is
needed to fully understand the potential similarities and differences between the
mutations in TAC1B and known mechanisms of fluconazole resistance in other species
of Candida. That withstanding, taken together, the findings of these studies serve to
demonstrate that mutations in TAC1B both represent a potent genetic determinant
contributing to clinical fluconazole resistance in C. auris and are prevalent among the
members of a large global collection of fluconazole-resistant clinical isolates. Further
studies characterizing the interplay between mutations in ERG11 and TAC1B and the
delineation of the TAC1B regulon in C. auris are needed.
MATERIALS AND METHODS
Isolate, strains, and growth media used in this study. Clinical isolates AR0387 and AR0390 were
made available by the CDC and FDA AR Isolate Bank as part of the C. auris collection of isolates. All
constructed strains and clinical isolates were grown in YPD liquid media (1% yeast extract, 2% peptone,
and 2% dextrose) at 30°C in a shaking incubator unless otherwise indicated. Frozen stocks of all strains
and clinical isolates were prepared with 50% sterile glycerol and were maintained at –80°C.
MIC determination. Fluconazole (Sigma) was prepared in dimethyl sulfoxide (DMSO). As previously
described, a modified version of the Clinical and Laboratory Standards Institute document M27 meth-
odology utilizing broth microdilution and RPMI liquid media and reading absorbance at 600 nm on a
BioTek Synergy 2 microplate reader (BioTek, Winooski, VT) was used to determine the fluconazole MIC
as the lowest concentration at which 50% inhibition of growth was obtained (36). All susceptibility
testing was performed in technical triplicate and biological duplicate.
Comprehensive sterol profiling. Fluconazole-evolved strains and the parental clinical isolate were
grown to the exponential-growth phase at 30°C in RPMI liquid media with or without fluconazole
supplemented at 16 mg/liter. Alcoholic KOH was used to extract nonsaponifiable lipids. A vacuum
centrifuge (Heto) was used to dry samples, which were then derivatized by adding 100 l 90%
N,O-bis(trimethylsilyl)-trifluoroacetamide–10% tetramethylsilane (TMS) (Sigma) and 200 l anhydrous
pyridine (Sigma) while heating at 80°C for 2 h as previously described (22, 34). gas chromatography-mass
spectroscopy (GC-MS) (with a Thermo 1300 gas chromatography system coupled to a Thermo ISQ mass
spectrometer; Thermo Scientific) was used to analyze and identify TMS-derivatized sterols through
comparison of the retention times and fragmentation spectra for known standards. Sterol profiles for
each sample were determined by analyzing the integrated peak areas from GC-MS data files using
Xcalibur software (Thermo Scientific). All sterol analysis was performed in biological triplicate. Error bars
for each data point represent the standard deviations of results from three independent measurements
of technical replicates.
Assessment of [3H]fluconazole uptake. C. auris isolates and fluconazole-evolved strains were
subjected to glucose starvation for 3 h, and 200-l volumes of concentrated cell pellets were added to
250 l of YNB without glucose and 50 l of freshly diluted 0.77 M [3H]fluconazole, yielding a final
[3H]fluconazole concentration significantly below the MIC of each strain or isolate being tested (23.6 pg/
liter). Samples were then incubated at 30°C for 24 h, after which 200 l of each sample was transferred
to 5 ml of stop solution (YNB plus 20 mM [6 mg/liter] unlabeled fluconazole) in a 14-ml round-bottom
tube. Samples were then filtered and dried on glass fiber filters and then washed with another 5 ml of
stop solution, and the filters and cells were then transferred to a 5-ml scintillation vial. A Beckman Coulter
scintillation analyzer was then used to quantify the radioactivity of each filter following the addition of
3 ml of scintillation cocktail (Ecoscint XR, National Diagnostics). Experiments were performed with six
biological replicates, and all results were normalized to cpm per 1 108 cells. Statistical comparisons
were made using a one-way analysis of variance (ANOVA) followed by a Tukey test, and the P values
presented represent adjusted values.
Assessment of copy number variation by qPCR and relative gene expression by reverse
transcription-quantitative PCR. For assessment of gene copy number variation, genomic DNA was
isolated from each isolate or strain, and qPCR was performed by the use of three independent primer sets
spanning the open reading frame of each gene of interest and the housekeeping gene ACT1, using SYBR
green per the manufacturer’s instructions and as previously described (26). For assessment of relative
gene expression levels, C. auris isolates and strains were inoculated into 2 ml of RPMI broth buffered with
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morpholinepropanesulfonic acid (MOPS) to pH 7.0 and grown overnight at 30°C for initiation. Overnight
cultures were then diluted to an optical density at 600 nm (OD600) of 0.1 in 10 ml of RPMI media with or
without 16 mg/ml of fluconazole and placed in a 50-ml conical tube. Cultures were then incubated for
10 h and then confirmed to be in the exponential-growth phase under these conditions, after which the
cells were collected by centrifugation, with storage of the cell pellets at –80°C until isolation of RNA was
performed. Synthesis of cDNA was performed using a RevertAid RT kit (Thermo Scientific) per the
manufacturer’s instructions. C. auris ACT1, ERG11, CDR1, and MDR1 were then amplified from cDNA using
SYBR green, PCR master mix, and previously described parameters (20). All experiments were performed
in biological and technical triplicate. The 2ΔΔCT method was used to calculate the relative levels of
expression of each gene of interest, and standard errors were determined using ΔCT values as previously
described (37, 38). Error bars for each data point represent standard errors of the means of results from
three biological replicates performed with three technical replicates. Statistical comparisons were made
using a one-way ANOVA followed by a Tukey test, and the P values presented represent adjusted values.
Primers are listed in Table S2 in the supplemental material.
Variant identification. TAC1A (B9J08_004819) and TAC1B (B9J08_004820) mutations were identified
in a set of 304 globally distributed Candida auris isolates representing clades I, II, III, and IV (27). For this
data set, analysis of read quality and filtering was performed using FastQC v0.11.5 and PRINSEQ v0.20.3
(39) with “-trim_left 15 -trim_qual_left 20 -trim_qual_right 20 -min_len 100 -min_qual_mean 25 -derep
14.” Then, paired-end reads were aligned to C. auris assembly strain B8441 (GenBank accession no.
PEKT00000000.2 [18]) using BWA mem v0.7.12 (40), and variants were identified using GATK v3.7 (41)
with the haploid mode and GATK tools (RealignerTargetCreator, IndelRealigner, HaplotypeCaller for both
single nucleotide polymorphisms [SNPs] and indels, CombineGVCFs, GenotypeGVCFs, GatherVCFs, Se-
lectVariants, and Variant Filtration). Sites were filtered with Variant Filtration using “QD 2.0  FS 60.0
 MQ 40.0.” Genotypes were filtered if the minimum genotype quality value was 50, the percent
alternative allele value was 0.8, or the depth value was 10 (https://github.com/broadinstitute/broad
-fungalgroup/blob/master/scripts/SNPs/filterGatkGenotypes.py). Genomic variants were annotated and
the functional effect predicted using SnpEff v4.3T (42). The annotated VCF file was used to determine the
genotype of known mutation sites in ERG11 (B9J08_001448) and mutations in TAC1A (B9J08_004819) and
TAC1B (B9J08_004820).
Antifungal susceptibility testing for global collection of isolates. Fluconazole susceptibility
testing was included for 294 of the 304 isolates included in whole-genome analyses. A total of 270
isolates were tested at the CDC as outlined by Clinical and Laboratory Standards Institute guidelines.
Briefly, custom prepared microdilution plates (Trek Diagnostics, Oakwood Village, OH, USA) were used for
fluconazole. Resistance to fluconazole was set at 32 mg/liter. This interpretive breakpoint was defined
based on a combination of these breakpoints with those established for other closely related Candida
species, epidemiological cutoff values, and the biphasic distribution of MICs between the isolates with
and without known mutations for antifungal resistance (https://www.cdc.gov/fungal/candida-auris/c
-auris-antifungal.html).
Cas9-ribonucleoprotein-mediated transformations. C. auris Cas9 and electroporation-mediated
transformations were performed as previously described (20) with minor modification. The C. auris TAC1B
alleles from AR0387 (TAC1BWT) and AR0390 (TAC1BA640V) were amplified from genomic DNA and then
cloned into plasmid pBSS2 using restriction enzymes SacII and EagI, yielding plasmids pBSS2-TAC1BWT
and pBSS2-TAC1BA640V. Repair templates for each allele of interest were then amplified from each plasmid
using primers that also introduced approximately 50 bases of homology targeting the TAC1B loci to the
3= end of the repair templates. Primers are listed in Table S2. Electrocompetent C. auris cells were
prepared as previously described. Approximately 4 M concentrations of dual Cas9-RNP constructs
targeting both the TAC1B allele and the sequence immediately downstream of the open reading frame
and 1 g of repair template were mixed with cells prior to electroporation performed according to the
C. albicans protocol on a GenePulsar Xcell (Bio-Rad) (24). Cells were then allowed to recover for 4 to 6 h
in YPD with incubation in a shaking incubator at 30°C. Transformants were then selected by plating
recovered cells on YPD plates supplemented with 400 g/ml of nourseothricin. Integration of the repair
template at the targeted loci was then confirmed by PCR for all transformants. The FLP recombinase was
then induced by growing positive-testing transformants in YPM (1% yeast extract, 2% peptone, and 2%
maltose) to mediate loss of the SAT1-FLP cassette. All final strains that were identified as having lost the
SAT1-FLP cassette by replica plating as previously described were then again confirmed by sequencing
(18).
Data availability. All data from Illumina sequences analyzed in this project are available in the NCBI
SRA under BioProject accession no. PRJNA328792, PRJNA470683, and PRJNA493622. A set of isolates are
available from the CDC and FDA Antimicrobial Resistance (AR) Isolate Bank (https://www.cdc.gov/
drugresistance/resistance-bank/index.html).
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
FIG S1, TIF file, 2.6 MB.
TABLE S1, DOCX file, 0.02 MB.
TABLE S2, DOCX file, 0.02 MB.
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